Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 401

1.

An open-label, randomized, multi-center study of the immunogenicity and safety of DTaP-IPV (Kinrix™) co-administered with MMR vaccine with or without varicella vaccine in healthy pre-school age children.

Klein NP, Weston WM, Kuriyakose S, Kolhe D, Howe B, Friedland LR, Van Der Meeren O.

Vaccine. 2012 Jan 11;30(3):668-74. doi: 10.1016/j.vaccine.2011.10.065. Epub 2011 Nov 4.

PMID:
22064267
2.

Immunogenicity and safety of a combined DTaP-IPV vaccine compared with separate DTaP and IPV vaccines when administered as pre-school booster doses with a second dose of MMR vaccine to healthy children aged 4-6 years.

Black S, Friedland LR, Schuind A, Howe B; GlaxoSmithKline DTaP-IPV Vaccine Study Group.

Vaccine. 2006 Aug 28;24(35-36):6163-71. Epub 2006 Apr 21.

PMID:
16759769
3.

Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.

Black S, Friedland LR, Ensor K, Weston WM, Howe B, Klein NP.

Pediatr Infect Dis J. 2008 Apr;27(4):341-6. doi: 10.1097/INF.0b013e3181616180.

PMID:
18316985
4.
5.

Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: a randomized, controlled study in infants in the Republic of Korea.

Lee SY, Hwang HS, Kim JH, Kim HH, Lee HS, Chung EH, Park SE, Ma SH, Chang JK, Guitton F, Ortiz E, Kang JH.

Vaccine. 2011 Feb 11;29(8):1551-7. doi: 10.1016/j.vaccine.2010.12.094. Epub 2011 Jan 6.

PMID:
21215828
6.

Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines.

Shinefield H, Black S, Thear M, Coury D, Reisinger K, Rothstein E, Xu J, Hartzel J, Evans B, Digilio L, Schödel F, Brown ML, Kuter B; 013 Study Group for ProQuad.

Pediatr Infect Dis J. 2006 Apr;25(4):287-92.

PMID:
16567978
8.

A comparison of booster immunisation with a combination DTPa-IPV vaccine or DTPa plus IPV in separate injections when co-administered with MMR, at age 4-6 years.

Marshall H, Nolan T, Roberton D, Richmond P, Lambert S, Jacquet JM, Schuerman L.

Vaccine. 2006 Aug 28;24(35-36):6120-8. Epub 2006 Jun 2.

PMID:
16822597
9.

Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with measles-mumps-rubella-varicella vaccine in children aged 12 to 16 months.

Vesikari T, Karvonen A, Lindblad N, Korhonen T, Lommel P, Willems P, Dieussaert I, Schuerman L.

Pediatr Infect Dis J. 2010 Jun;29(6):e47-56. doi: 10.1097/INF.0b013e3181dffabf.

PMID:
20508478
10.

Immunogenicity and safety of a DTaP-IPV//PRP-T vaccine (Pentaxim) booster during the second year of life in Thai children primed with an acellular pertussis combined vaccine.

Thisyakorn U, Pancharoen C, Chuenkitmongkol S, Ortiz E.

Southeast Asian J Trop Med Public Health. 2009 Mar;40(2):282-94.

PMID:
19323013
11.

Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants.

Madhi SA, Koen A, Cutland C, Groome M, Santos-Lima E.

Pediatr Infect Dis J. 2013 Aug;32(8):889-97. doi: 10.1097/INF.0b013e318292f7b1.

PMID:
23538523
12.

Safety and immunogenicity of a pentavalent diphtheria, tetanus, pertussis, hepatitis B and polio combination vaccine in infants.

Yeh SH, Ward JI, Partridge S, Marcy SM, Lee H, Jing J, Curry ES, Howe BJ.

Pediatr Infect Dis J. 2001 Oct;20(10):973-80.

PMID:
11642632
13.
14.

New combination vaccines: DTaP-IPV (Kinrix) and DTaP-IPV/Hib (Pentacel).

Johns TL, Hutter GE.

Ann Pharmacother. 2010 Mar;44(3):515-23. doi: 10.1345/aph.1M468. Review.

PMID:
20197476
15.
16.
17.

Antibody persistence at 18-20 months of age and safety and immunogenicity of a booster dose of a combined DTaP-IPV//PRP∼T vaccine compared to separate vaccines (DTaP, PRP∼T and IPV) following primary vaccination of healthy infants in the People's Republic of China.

Li RC, Li FX, Li YP, Hou QM, Li CG, Li YN, Chen FS, Hu XZ, Su WB, Zhang SM, Fang HH, Ye Q, Zeng TD, Liu TX, Li XB, Huang YN, Deng ML, Zhang YP, Ortiz E.

Vaccine. 2011 Nov 21;29(50):9337-44. doi: 10.1016/j.vaccine.2011.09.131. Epub 2011 Oct 14.

PMID:
22001281
18.
19.

A fully liquid DTaP-IPV-Hep B-PRP-T hexavalent vaccine for primary and booster vaccination of healthy Mexican children.

Aquino AG, Brito MG, Doniz CE, Herrera JF, Macias M, Zambrano B, Plennevaux E, Santos-Lima E.

Vaccine. 2012 Oct 5;30(45):6492-500. doi: 10.1016/j.vaccine.2012.07.040. Epub 2012 Jul 31.

PMID:
22863658
20.

Immunogenicity and safety of a combined measles, mumps, rubella and varicella live vaccine (ProQuad ®) administered concomitantly with a booster dose of a hexavalent vaccine in 12-23-month-old infants.

Deichmann KA, Ferrera G, Tran C, Thomas S, Eymin C, Baudin M.

Vaccine. 2015 May 11;33(20):2379-86. doi: 10.1016/j.vaccine.2015.02.070. Epub 2015 Mar 9.

PMID:
25765966

Supplemental Content

Support Center